ESCC stands for esophageal squamous cell carcinoma, a major histologic subtype of esophageal cancer arising from squamous epithelial cells lining the esophagus. It is epidemiologically distinct from esophageal adenocarcinoma, with different geographic patterns and risk factors. ESCC is more common in many developing regions.
CStone Pharmaceuticals received FDA IND clearance to initiate a Phase II trial of CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors across nine cancer indications.
CStone Pharmaceuticals received FDA IND clearance to begin a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGF, and CTLA-4, in advanced solid tumors across nine cancer indications.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07770672 |
An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging |
NOT_YET_RECRUITING | PHASE2 |
| NCT07701681 |
Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07627347 |
Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC) |
RECRUITING | NA |
| NCT07584031 |
Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07533305 |
Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07531979 |
Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 |
NOT_YET_RECRUITING | PHASE2 |
| NCT07524374 |
SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy |
NOT_YET_RECRUITING | PHASE2 |
| NCT07493993 |
Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07388095 |
Adebrelimab Neoadjuvant Treatment for Resectable ESCC |
NOT_YET_RECRUITING | NA |
| NCT07266363 |
Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma |
RECRUITING |
